• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
【24h】

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma

机译：用roltitrexed和Nedaplatin治疗食管鳞状细胞癌的同时进行化学疗法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The aim of the study reported here was to evaluate the feasibility and safety of raltitrexed and nedaplatin with concurrent radiotherapy in patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC). Methods: Eligible patients were adults with newly diagnosed untreated, unresectable esophageal cancer in stages I to IV with lymph node metastases or cervical esophageal cancer . Patients received nedaplatin 25 mg/m 2 per day on day 1–3, raltitrexed 3 mg/m 2 on days 1 repeated every 21 days for 2 cycles, and combined concurrent radiotherapy (2 Gy/fraction, total dose of 60 Gy). Result: Thirty patients were included with squamous cell carcinoma. The median follow-up duration was 24 months. The overall response rate was 90%. The 1-year and 2-year overall survival rates for all patients were 70.4% and 55.7% with a median survival time of 30 months, and the median progression free survival was 20 month. The major toxicities were leukopenia and thrombopenia, with grade 3 to 4 leukopenia and thrombopenia were 50% and 30% of patients. Conclusion: Concurrent chemoradiotherapy with raltitrexed and nedaplatin agents frequently caused myelosuppression but was highly active and suggested to be a promising treatment option for locally advanced ESCC.
机译：背景：本研究的目的是评估罗尔特拉特雷德和Nedaplatin的可行性和安全性与不可切除的局部晚期食管鳞状细胞癌（ESCC）的患者同时放射治疗。方法：符合条件的患者是具有新诊断的未经治疗的未切除的，在IV阶段的未切除的食管癌的成年人，淋巴结转移或宫颈食管癌。每天1-3天每天接受Nedaplatin 25mg / m 2，每21天重复3mg / m 2，每21天重复2次循环，并组合同时放射疗法（2 Gy /级分，60 Gy的总剂量）。结果：三十名患者含有鳞状细胞癌。中位后续时间为24个月。整体反应率为90％。所有患者的1年和2年整体生存率为70.4％和55.7％，中位生存时间为30个月，中位进展免费生存率为20个月。主要毒性是白细胞减少和血栓形成，3至4级白细胞减少症和血栓形成为50％和30％的患者。结论：与罗尔特拉特雷德和Nedaplatin患者的同步化学疗法经常引起髓抑制，但具有高度活跃，并建议成为当地先进的ESCC的有希望的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号